Ken Schultz
Principal Scientist
Novartis
Ken Schultz is a principal scientist in Oncology Translational Research at Novartis. He started with Novartis in 2012 as part of Oncology Precision Medicine. Most recently, he has led the implementation of multiple digital pathology workflows and AI platforms for research and early clinical trial biomarker work. He holds a BS in Biology from Seattle University..